Gastric cancer is the fourth most common cancer in the world in terms of cancer mortality, threatening people's health and safety. Advanced gastric cancer cannot be eradicated by surgery, and the effect of traditional treatment is not satisfactory. Targeted therapy and immunotherapy have become promising new treatment modalities, but there are fewer therapeutic targets for gastric cancer. We screened existing datasets related to gastric cancer treatment and drug resistance to identify novel therapeutic targets. We analyzed three gastric cancer chemotherapy related datasets using bioinformatics and identified 28 significantly differentially expressed genes for further analysis. The results of the analysis showed that CDH11, SRPX and TPM2 were independent significant factors that were highly associated with poor prognosis of overall survival in gastric cancer. Gene expression and tumour stemness analysis showed that SRPX and TPM2 were highly correlated in gastric cancer. Immune infiltration score analysis showed that SRPX had higher immune infiltration than TPM2 in gastric cancer. The analysis results suggested that SRPX is a potential target for novel targeted therapy and immunotherapy in gastric cancer.